A promising new drug developed right here at The James is showing remarkable success with certain leukemia patients. According to leukemia expert Dr. John Byrd, the drug known as acalabrutinib is a targeted medicine that goes after a protein found in chronic lymphocytic leukemia (CLL) and can actually turn that protein off—leading to remarkable patient response and often a return to regular daily activities.